Cyclerion Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Regina Graul
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 First Street Cambridge MA United States of America 02142
- IPO Date
- Mar 18, 2019
- CIK
- 0001755237
- Website
- cyclerion.com
- Similar Companies
- Business
- Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical entity that has recently undergone a strategic transformation to concentrate on developing innovative therapies for neuropsychiatric conditions. The company’s core focus has shifted to building a new pipeline, with its foundational product candidate being an individualized therapeutic approach for treatment-resistant depression (TRD). This lead program, which is Phase 2-ready, leverages common anesthetic agents alongside a proprietary, technology-driven system to restore functional connectivity by resynchronizing communication between key brain regions. A Phase 2 proof-of-concept trial for this program is projected to commence in 2026, with initial data anticipated in 2027. This strategic pivot follows a licensing agreement with the Massachusetts Institute of Technology (MIT) and a move away from its historical portfolio of soluble guanylate cyclase (sGC) stimulators, such as CY6463, Praliciguat, and Olinciguat, which have been out-licensed or sold to other entities. Founded in 2019, the company maintains its headquarters in Cambridge, Massachusetts.
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ)
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates